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Soluble antigens diffuse out of the brain and can thus stimulate
a systemic immune response, whereas particulate antigens (from
infectious agents or tumor cells) remain within brain tissue, thus
failing to stimulate a systemic immune response. Immune privilege
describes how the immune system responds to particulate anti-
gens localized selectively within the brain parenchyma. We believe
this immune privilege is caused by the absence of antigen pre-
senting dendritic cells from the brain. We tested the prediction
that expression of fms-like tyrosine kinase ligand 3 (Flt3L) in the
brain will recruit dendritic cells and induce a systemic immune
response against exogenous influenza hemagglutinin in BALB/c
mice. Coexpression of Flt3L with HA in the brain parenchyma
induced a robust systemic anti-HA immune response, and a small
response against myelin basic protein and proteolipid protein
epitopes. Depletion of CD4+CD25+ regulatory T cells (Tregs) en-
hanced both responses. To investigate the autoimmune impact
of these immune responses, we characterized the neuropatholog-
ical and behavioral consequences of intraparenchymal injections
of Flt3L and HA in BALB/c and C57BL/6 mice. T cell infiltration in
the forebrain was time and strain dependent, and increased in
animals treated with Flt3L and depleted of Tregs; however, we
failed to detect widespread defects in myelination throughout
the forebrain or spinal cord. Results of behavioral tests were all
normal. These results demonstrate that Flt3L overcomes the brain’s
immune privilege, and supports the clinical development of Flt3L
as an adjuvant to stimulate clinically effective immune responses
against brain neo-antigens, for example, those associated with
brain tumors.
immune response | dendritic cells | influenza hemagglutinin | regulatory
T cells | perivascular cuffs
The CNS, the anterior chamber of the eye, and the testis areclassified as immune-privileged organs (1). Immune privilege is
thought to protect organs with limited regenerative capacity from
immune attack (1–4), but has the consequence of reduced immune
surveillance of the brain for neo-antigens associated with viruses or
tumors. In the brain, the absence of conventional lymphatic drain-
age, low levels of constitutive expression of MHC class I and class II
molecules (5), production of powerful immunosuppressive factors
such as TGF-β (6), or factors that activate regulatory T cells (Tregs)
(7), and, perhaps most importantly, scarcity of resident professional
antigen presenting cells, i.e., dendritic cells (DCs) (8), all contribute
to the particular immune responsiveness of the brain (3). Although
the blood–brain barrier is important in regulating the traffic of ions
and large molecules into the brain, it plays a limited role in de-
termining the brain’s immune responsiveness (9).
Importantly, the immune privilege of the brain is restricted to
the parenchyma, whereas the ventricles, choroid plexus, menin-
ges, and cerebrospinal fluid display the full range of innate and
adaptive immune responses, because they contain the requisite
immune structures and cells (3, 9–11). Soluble antigen will dif-
fuse from the brain parenchyma to the ventricles, will be taken
up by DCs, which migrate to the cervical lymph nodes, and will
initiate an immune response (12–14). However, large particulate
antigens are unable to diffuse out of the brain parenchyma. For
example, the immune response to live influenza virus depends on
the injection site (15); injection into the ventricles immediately
causes immune priming, but injections into the brain parenchyma
do not, until the infection breaks into the ventricles. Careful
injections of bacillus Calmette–Guérin, a particulate nonsoluble
antigen (16, 17), or adenoviral vectors, directly into the brain
parenchyma do not stimulate specific systemic immune responses,
whereas injections into the ventricles do (18, 19). Nevertheless,
injections into the brain parenchyma will induce innate immune
responses (e.g., cytokine release, TLR activation) restricted to the
brain (20–23).
Once the systemic immune system has been primed through
peripheral exposure to antigen, effector lymphocytes have few re-
strictions in entering the brain and eliminating cells expressing
their cognate antigens (24, 25). The possibility therefore arises that
if the population of DCs in the brain could be increased, immune
surveillance of the brain would be improved. One candidate for
increasing numbers of DCs is the cytokine fms-like tyrosine kinase
ligand 3 (Flt3L), which induces the development of DCs from
monocyte precursors (26). We have previously shown that in-
jection of Flt3L results in the recruitment of DCs into normal rat
brain tissue (27). When combined with cytotoxic approaches such
as herpes simplex type 1 thymidine kinase (TK) and gancyclovir
(GCV), intratumoral expression of Flt3L elicits an anti–brain-
tumor immune response in mice (28, 29).
In this study, we explored the mechanistic basis of this treat-
ment, by testing whether Flt3L can overcome the brain’s immune
privilege and enable a systemic T cell immune response against
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an antigen expressed exclusively in the brain parenchyma. Ex-
pression of the influenza glycoprotein hemagglutinin within the
brain parenchyma induced only a systemic HA-specific immune
response when coexpressed with Flt3L.
Regulatory T cells are another component of the brain’s im-
mune privilege, acting to prevent excessive damage of healthy
tissue, but also potentially suppressing the antiviral and antitumor
immune responses (30). We compared the effect of depletion of
CD4+CD25+ Tregs independently, or combined with Flt3L ad-
ministration, and found that the two treatments synergized in
augmenting the immune response against HA.
We also found that expression of Flt3L in the brain parenchyma
elicited a small systemic immune response against myelin basic
protein (MBP) and proteolipid protein 1 (PLP) epitopes. How-
ever, such immune responses, which were increased by Treg de-
pletion, were insufficient to induce behavioral deficits typical of
experimental allergic encephalomyelitis, even though brain in-
flammation was increased. These results suggest that Flt3L can be
used to break the immune privilege of the brain parenchyma, and
support its use to stimulate immune responses against novel anti-
gens, such as are expressed by brain tumors, or virally infected
cells. Furthermore, the restricted CNS inflammation and absence
of behavioral deficits support the continued development of com-
bined cytotoxic/immunostimulatory anti-glioma therapy that will
begin phase I clinical testing in the upcoming year.
Results
Striatal Expression of HA Alone Fails to Elicit a Substantial Immune
Response. We first tested the prediction that expression of a neo-
antigen in the brain parenchyma does not induce a systemic im-
mune response. Ad.HA was injected into the brain striatum, or
into the cerebral ventricles. Seven days later, animals were killed,
and splenocytes were stimulated with the HA class I peptide, the
HA class II peptide, or His-HA protein and analyzed by ELI-
SPOT (Fig. 1A) and T cell proliferation assays (Fig. 1B). Animals
injected with Ad.HA in the striatum revealed a minimal increase
in the frequency of HA-specific IFNγ-secreting T lymphocytes
(Fig. 1A), and no HA-specific T cell proliferation (Fig. 1B). As
predicted, ventricular administration of Ad.HA resulted in the
induction of a massive HA-specific immune response.
Intrastriatal Flt3L Induces a Systemic HA-Specific Immune Response.
In the experimental autoimmune encephalomyelitis model (EAE)
model of multiple sclerosis, systemic delivery of Flt3L results in an
increase of circulating and meningeal DCs, and a more severe
disease phenotype (31) (32). In a brain tumor model, we have
previously demonstrated that Ad.Flt3L recruits DCs to the brain
and, together with Ad.TK, induces an antiglioma immune re-
sponse. One possible way in which Flt3L might accomplish this is
by overcoming the brain’s immune privilege. To investigate this
possibility, we assessed whether striatal expression of Flt3L would
enable recognition of HA expressed in the brain striatum. We
injected BALB/c mice intrastriatally with Ad.HA with or without
coadministration of Ad.Flt3L. Seven days later, animals were kil-
led, and splenocytes were stimulated with either the HA class I
peptide, the HA class II peptide, or His-HA protein and then
analyzed by ELISPOT (Fig. 1C) and T cell proliferation (Fig. 1D).
Coadministration of Ad.Flt3L with Ad.HA into the brain striatum
caused a large increase in the frequency of HA-specific, IFNγ-
secreting T lymphocytes (Fig. 1C) and HA-specific T cell pro-
liferation (Fig. 1D). To examine the possibility that the effect of
FLt3L is mediated by recruitment of DCs, we assessed by flow
cytometry the frequency of CD11c+ cells infiltrating the striata of
animals injected with Ad.HA and either Ad.Flt3L, or a control
vector with no transgene (Ad.0) (Fig. 1 E–G). Injection of either
combination of vectors resulted in a large increase in CD45+ cells
in the brain compared with that in animals injected with saline
(Fig. 1F), but only in the animals injected with Ad.FLt3L was the
fraction of these cells expressing CD11c (DCs) increased com-
pared with controls (injected with saline or Ad.0) (Fig. 1G).
Expression of Flt3L in Striatum Induces Immune Response against Brain
Antigens. As Flt3L induced an immune response against a neo-
antigen restricted to the brain parenchyma, we asked whether the
immune response would also target brain protein self-epitopes.
Fig. 1. Immune privilege of brain parenchyma can be overcome by Flt3L. (A)
Seven days after injection into striatum (hatched bars) or into ventricle (solid
bars), splenocytes were stimulatedwith either theHA class I peptide, HA class II
peptide, or His-HA protein or unstimulated before quantification of IFNγ
production by ELIspot. ^P < 0.05 vs. corresponding no stimulation group; *P <
0.05 vs. splenocytes from intrastriatally injected animals incubated with same
stimuli; n = 5/group. (B) Splenocytes were stimulated with either the HA class I
peptide, HA class II peptide, or His-HA protein, or as controls, unstimulated.
BrdU incorporation into nascent DNA strands was measured by ELISA to de-
termine relative proliferation of T lymphocytes (vertical axis represents optical
density). ^P < 0.05 vs. corresponding no stimulation group; *P < 0.05 vs.
splenocytes from intrastriatally injected animals incubated with same stimuli;
n = 5/group. (C and D) HA-specific immune response in animals injected in
striatal parenchyma with Ad.HA alone (hatched bars), or with coinjection of
Ad.FLt3L (solid bars). Seven days after injection, cells were isolated from
spleens and characterized by ELIspot (C) or T cell proliferation assay (D). Layout
and statistics for these figures are identical toA and B. Error bars indicate SEM.
(E) Representative flow cytometry dot plots showing effect of Flt3L injection
on numbers of CD45 and CD11c immunopositive cells infiltrating the brain.
Intact cells were gated on forward and side scatter. First panel shows cells in-
cubated with control antibodies; remaining four panels show, from left to
right, cells fromanimals injectedwith saline, 6×107Ad.0, 1× 107Ad.HA+5× 107
Ad.0, and1× 107Ad.HA+ 5× 107Ad.Flt3L. Numbers of cells in rectanglemarked
R2 were used to prepare column scatter graph in G. (F) Percentage of live cells
extracted from brains immunopositive for CD45, by group. *P < 0.05 vs. saline;
^P< 0.05 vs. Ad.0 or HA+Ad.0. (G) Percentage of CD45+ cells also CD11c positive.
*P < 0.05 vs. saline. Data from individuals closest to mean valuewere chosen for
representative dot plots in E.
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Splenocytes from BALB/c mice injected intrastriatally with either
Ad.HA alone or Ad.HA + Ad.Flt3L and killed at 1 or 2 wk were
analyzed by ELISPOT and T cell proliferation assays using self-
antigens MBP and PLP as stimuli. At 1 wk, the response to self-
epitopes was minimal and not influenced by Flt3L in an antigen-
specific way (SI Appendix, Fig. S3). At 2 wk, Flt3L treatment had
increased the number of T lymphocytes secreting IFNγ (Fig. 2A) in
response to MBP or MBP peptide, but not PLP, and T cell pro-
liferation (Fig. 2B) in response to MBP or PLP. There was also
a small increase in IFNγ spots in the unstimulated group (Fig. 2A),
suggesting that Flt3L administration increases the nonspecific
immune reactivity, not just the antigen-specific response, although
the interaction between stimulus and Flt3L treatment in a two-way
ANOVA (P < 0.017) implies antigen dependence, reflected in the
lack of response to PLP.
Depletion of Regulatory T Cells Enhances Immune Responses Against
Neo- and Self-Antigens following Delivery of Flt3L. The contribution
of Tregs to the initiation and resolution of the EAE disease
phenotype has been widely studied (33–35), and depletion of
CD4+CD25+ Tregs exacerbates clinical symptoms of EAE in
mice (36, 37). We wished to assess the effect of Treg depletion
on the induction of neo-antigen or self-antigen specific immune
responses in Flt3L-treated animals. Depletion of CD4+CD25+
Tregs with the rat monoclonal anti-CD25 antibody PC-61 sig-
nificantly increased the systemic immune response against a neo-
antigen only in animals receiving a striatal injection of Ad.Flt3L
(Fig. 2C). When splenocytes from these animals were stimulated
with peptides derived from MBP or PLP, an increase in the
frequency of IFNγ secreting T lymphocytes specific for self-brain
antigens was also observed (Fig. 2D).
Flt3l Treatment and Treg Depletion Do Not Induce Overt Demyelination
orBehavioralAbnormalities. In view of the discovery of elevated levels
of self-reactive T cells in Flt3L-treated mice, especially in animals
depleted of Tregs, the possibility of auto-immune damage was in-
vestigated in detail. First, in addition to the 2-wk time point, another
cohort of animals was maintained until 2 mo after vector injection
and Treg depletion, to enable any autoimmune effects to become
more obvious. Second, behavior of animals was tested systematically
at the 2-mo time point. Third, the experiment was repeated using
Fig. 2. Minor immune response against self-brain antigen is induced by in-
jection of Ad.Flt3L andHA, and augmented by Treg depletion. (A and B) Ad.HA
alone (openbars)orAd.HA+Ad.Flt3L (filledbars)were injected in the left striata
of BALB/c mice. (A) Fourteen days after vector injection, splenocytes were
stimulated with MBP pure protein, the MBP 59–67 peptide, or the PLP 139
peptide, or unstimulated before quantification of IFNγ production by ELIspot.
*P < 0.05 vs. splenocytes from Ad.HA-injected animals (i.e., no Flt3L) incubated
with same stimulus; ^P < 0.05 vs. corresponding no stimulation group; n = 5/
group. (B) Splenocytes were stimulated with MBP pure protein, MBP 59–67
peptide, or PLP 139 peptide, or as controls, unstimulated. BrdU incorporation
into nascent DNA strandswasmeasured to determine relative proliferation of T
lymphocytes lymphocytes (vertical axis represents optical density). *P < 0.05 vs.
splenocytes from Ad.HA-injected animals (i.e., no Flt3L) incubated with same
stimuli; ^P< 0.05 vs. corresponding no stimulationgroup;n = 5/group. (C andD)
Effect of Treg depletion. Ad.HA alone (open bars) or Ad.HA + Ad.Flt3L (filled
bars) was injected into the left striata of BALB/c mice. Tregs were depleted by
systemic administration of PC-61 or with saline as a control. Two weeks later,
animals were euthanized and splenocytes were isolated for ELISPOT assays. (C)
The frequency of HA-specific IFNγ secreting T lymphocytes was quantified after
stimulation with either the HA class I peptide, HA class II peptide, or His-HA
protein, or as controls, unstimulated. *P < 0.05 vs. saline depletion of the same
vector treatment and stimulation group; ^P < 0.05 vs. splenocytes from Ad.HA-
injected (i.e., no FLt3L) animals in the same depletion and stimulation group;
n = 5. (D) Frequency ofmyelin or PLP-specific, IFNγ-secreting T lymphocytes was
quantified following stimulationwithMBPpure protein,MBP59–67peptide, or
PLP 139 peptide, or as controls, unstimulated. Data were analyzed by two-way
ANOVAfollowedbyTukey–Kramermultiple comparisontest. *P<0.05vs. saline
depletion of same vector treatment and stimulation group; ^P < 0.05 vs. sple-
nocytes from Ad.HA-injected (i.e., no Flt3L) animals in the same depletion
and stimulation group; n = 5/group. Error bars indicate SEM.
Fig. 3. Myelin lesions in C57BL/6and BALB/c mice injected with Flt3L and
depleted of Tregs are restricted to injected hemisphere and do not affect
behavior. (A) Coronal brain sections immunolabeled for MBP from C57BL/6
mice injected with 1 × 107 Ad.HA + 5 × 107 Ad.0 and treated with a control
antibody (Left), or 1 × 107 Ad.HA + 5 × 107 Ad.Flt3L and PC-61 (Right). Yellow
arrows on right image indicate destruction of white matter in injected
hemisphere (injection); black arrow shows intact white matter contralaterally
(contra). Little damage is visible in the animal not treated with FLt3L or PC61
(Left). (B) Ambulatory activity of mice in open field trials. Vertical axis shows
number of times that mice crossed light beams in a 60-min trial. Left four
columns show data from BALB/c mice; right four columns show data from
C57BL/6mice. *P < 0.05 vs. group treatedwith Ad.HA only (i.e., no Flt3L or PC-
61). (C). Rearing data do not show any behavioral effects of treatments. (D)
Mice were placed on a rod that was then rotated at slowly increasing speed
until themouse fell. Latency to fall was recorded (vertical axis). There were no
statistically significant differences between groups.








C57BL/6mice in addition toBALB/c, asC57BL/6mice are reported
to be more susceptible to EAE (38).
Myelin morphology was examined by MBP immunohistochem-
istry (Fig. 3A; taken from the 2-mo time point). The noninjected
hemispheres did not show any damage in any of the groups. The
injected hemispheres, however, displayed some signs of localized
damage at the 2-wk and 2-mo time points, being of a significant
nature in animals treated with both Flt3L and Treg depletion.
At 2 mo, animals were subjected to a battery of psychomotor
tests. In both strains in all four groups, righting response, eye blink,
ear twitch, startle response, and olfactory and visual orienting were
all normal at 2 mo, and every animal was able to hang onto a wire
for 30 s without falling, with the single exception of one BALB/c
mouse treated with Flt3L alone, which fell from the wire after 8 s.
This mouse was unremarkable in any other measure. Immediately
before being killed at 2 mo, all mice were able to hold up their tails
with no sign offlaccidity, andwere able to grip a wire cagewith each
of their hind feet. In open field trials, all mice, regardless of group,
were similarly active (Fig. 3 B and C), although the BALB/c group
treated with PC-61 alone was slightly more active (Fig. 3B, Left).
All animals were able to remain on a rotating rod for a similar
length of time (Fig. 3D). No other significant differences among
groups were found.
Brains from all animals were immunolabeled for CD3ε (a pan-T
cell marker) to reveal infiltrating T cells as a measure of in-
flammation (Fig. 4), and T cells counted in the injected striatum
(Fig. 4 C and D) and the contralateral cortex and corpus callosum
(Fig. 4E andF).At 2wk, thepatternofT cell infiltrationwas similar
between strains, being minimal in animals receiving HA only, and
maximal in animals depleted of Tregs and given Flt3L (Fig. 4A and
B,Top, andCandD,Left).At2mo, in the injectedhemispheres, the
patterns differeddramatically between strains; in theBALB/cmice,
T cell infiltration was substantially less than at 2 wk, whereas in the
C57BL/6 it had increased. In the contralateral hemispheres there
were essentially no T cells present at 2 wk, but they were increased
at 2mo inboth strains in animals treatedwithFlt3Landdepletedof
Tregs. One animal in particular, from the Flt3L-treated, Treg de-
pleted group had very extensive T cell infiltration in both hemi-
spheres, and this animal was characterized further by immuno-
fluorescent labeling for MBP and CD3ε. Numerous T cells were
found scattered diffusely throughout the cortex (Fig. 5A), or con-
centrated in clusters (Fig. 5 B and C). The relationship between
these clusters and blood vessels was investigated with double
immunolabeling for CD3ε and laminin; clusters of T cells were
localized to perivascular cuffs (Fig. 5D). At 2 wk, these perivascular
cuffswere foundonly on the injected side (Fig. 5E,Left),whereas in
the contralateral hemisphere T cells were very sparse and mostly
restricted to the region of the external capsule (Fig. 5E, Middle).
However, in the animal with the greatest T cell infiltration at 2 mo,
these clusters could also be seen in the contralateral cortex (Fig. 5E,
Right). As T cells usually target the spinal cord in EAE, we exam-
ined segments of thoracic and cervical spinal cords from all mice
from the group that displayed the most contralateral inflammation,
i.e., C57BL/6, 2 mo postinjection of Flt3L and Treg depletion. T cells
were only found in the cervical spinal cord of the one animal with the
highest contralateral brain inflammation, within an area of the dorsal
spinal cord corresponding to the cortico-spinal tract (SI Appendix, Fig.
S4).We sawnoTcell infiltration in the anterior horn, as is usually seen
Fig. 4. T cell infiltration at 2 wk and 2 mo following adminis-
tration of Ad.HA and Ad.Flt3L, and depletion of Tregs with PC61.
(A) Coronal sections of BALB/cmice injectedwith combinations of
vectors and antibodies indicated at top of figure and perfused at
timepoint indicatedat left offigure and immunolabeled for CD3ε
(pan-T cellmarker). Images are froma representative section from
thebrainmost extensively infiltratedwithT cells fromeachgroup.
Injected hemisphere (injection), noninjected hemisphere (contra),
and scale bar representing 1 mm are all indicated (Top Left) and
are the samethroughout. (B) Sections fromC57BL/6mice.Layout is
identical to that in A. Yellow arrows (Bottom Right) indicate in-
filtration in the contralateral hemisphere. Insets, Top Right in
rightmost panels, are higher-ower images of contralateral exter-
nal capsule, showing degree of T cell infiltration. (Scale bar,
100 μm.) (C) Numbers of CD3ε immunoreactive T cells in injected
striatum of each BALB/c mouse by time point and treatment
group. Cells were counted in the most extensively infiltrated sec-
tion and expressed as number per square millimeter of area of
striatum in that section. *P< 0.05vs. Ad.HA (i.e., no Flt3L or PC-61)
group at same time point; ^P < 0.05 vs. equivalent group at 2-mo
time point. (D) Corresponding counts for C57BL/6 mice. *P < 0.05
vs. Ad.HA group at same time point; ^P < 0.05 vs. Ad.HA+PC-61
group. (E and F) Similar counts for contralateral cortex + corpus
callosum. This area was chosen because it contained noticeably
more T cells than the contralateral striatum. *P < 0.05 vs. Ad.HA
group at same time point. One C57BL/6mouse had very extensive
T cell infiltration in the contralateral cortex (B, BottomRight), and
the count for this animal is plotted in F with a filled circle at an
arbitrary location, with the numerical value indicated beside the
plotted point to facilitate graphing; similarly, as themean for this
group is off-scale, the mean is represented with a bar in an arbi-
trary location with its numerical value beside the bar. Disparate
intergroup variance in this dataset, even following log or other
transformation, precluded analysis of variance.
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in EAE.We conclude that the T cells in the spinal cord of this animal
are most likely infiltrating in response to inflammation caused by
degenerating cortico-spinal axons following forebrain inflammation
and potential tissue destruction.
Discussion
The data described demonstrate that expression of Flt3L in the
brain overcomes the brain’s immune privilege, i.e., enables a systemic
immune response specifically against an antigen the expression of
which is restricted to the brain parenchyma. This result is significant
because the brain’s immune privilege is likely to limit effective anti–
brain-tumor immune therapies.We have previously described a treat-
ment in which Ad.Flt3L and Ad.TK are injected into brain tumors in
rodents (28, 29). In several model systems, this treatment induces
a potent, systemic, clinically effective, and specific antiglioma immune
response, without untoward autoimmune effects, but the mechanism
bywhich Flt3L asserts its effect is still an active research question. The
experiments described in this paper were designed to answer three
questions: (i) whether Flt3L expression enables a systemic immune
response specifically against an antigen expressed solely within the
brain parenchyma; (ii) if so, how this effect compareswith the effect of
depleting Tregs; and (iii) whether either of these treatments results in
harmful autoimmune responses.
The model antigen HA was chosen because of the well-charac-
terized class-I– and class-II–restricted immune responses in BALB/
c mice, and was expressed from a recombinant adenovirus. As
expected, injection of Ad.HA into the striatum did not cause sys-
temic anti-HA immune responses. As a positive control, Ad.HA
was injected into the ventricles and induced a robust systemic anti–
HA-specific immune response. Using this paradigm of brain im-
mune privilege, we tested the effect of coadministration of Ad.
Flt3L, and found that it enables a strong systemic immune response
against HA expressed within the brain parenchyma, i.e., overcomes
immune privilege. To test the hypothesis that this effect ismediated
by recruitment of DCs to the brain, we assessed numbers of DCs in
animals injected with Ad.Flt3L and confirmed that the DC num-
bers were increased. This finding does not prove that DCs are
causally involved in the breakdown of immune privilege but is
consistent with this possibility.
The fact that a robust systemic anti-HA immune response can be
induced by coadministration with Flt3L raised the question of
whether it also induces an autoimmune response against endoge-
nous brain antigens. Analysis of the frequency of IFNγ secreting T
lymphocytes and T cell proliferation in response to stimulation with
MBP and PLP revealed a small immune response against these
antigens, and brain infiltration by CD3ε + T cells. The effect of
Treg depletion by itself was generally minor but, in combination
with Flt3L, resulted in a stronger immune response to both exog-
enous and self-antigens. However, Flt3L and depletion of Tregs
failed to induce the kind of motor deficits, demyelination, or spinal
cord inflammation normally associated with EAE. These results
strongly suggest that Flt3L administration increases immune re-
activity against antigens in the brain parenchyma, whether endog-
enous or exogenous, and that in combination with Treg depletion
results in long-term inflammation. However, the evidence for del-
eterious autoimmunity is not definitive, as any of the effects that we
observed could be due to the combination of enhanced immune
reactivity and the anti-HA immune response. Resolving this issue
beyond reasonable doubt may require experiments involving adop-
tive transfer of immune cells from Flt3L-treated, Treg-depleted
donors into naive, syngeneic hosts.
Overall, our data indicate that an immune response against
antigens localized to the brain, such as those expressed by brain
tumors or virus, could be stimulated by administration of Flt3L in-
tracranially and enhanced by depletion of Tregs. These data are
consistent with previous work from our group indicating that com-
bined use of Flt3L + TK (+ ganciclovir) to treat unilateral intra-
cranial brain tumors induces an effective anti–brain-tumor immune
responsewithout overt autoimmunity (37–42), and thedata strongly
support the addition of Flt3L as an adjuvant to cytotoxic and im-
munostimulatory approaches currently under evaluation for the
treatment of human malignant brain tumors.
Methods
Adenoviral Vectors. Ad.Flt3L and Ad.0 have been described elsewhere (28, 43).
The HA cDNA plasmid provided by A. Caton (Wistar Instute, Philadelphia, PA)
was cloned into the adenoviral vector shuttle plasmid pΔE1sp1a (Microbix).
The first-generation adenoviral vector Ad.HA was rescued by cotranfection
with pJM17 and amplified and purified as described previously (39). Cloning
details and characterization of the vector are described in SI Appendix, SI
Methods, and the vector is depicted schematically in SI Appendix, Fig. S1.
Stereotactic Injection of Adenoviral Vectors and Treg Depletion. All animal
experimentswere approved by the InstitutionalAnimal Care andUseCommittee
at Cedars-SinaiMedical Center.Micewere injectedwith vectors or saline into the
left striatum(+0.5mmAP,–2.2mmML,–3.0mmDVfromthebregma)orventricle
(+0.8mmAP, +1mmML, –2.0mmDV from the bregma), as described previously
(40). TodepleteCD25+Tregs,micewere treatedwitha single i.p. injectionof1mg
ascites fluid (600 μL) from the PC61 hybridoma (41). Results of a pilot experiment
confirmingdepletionof Foxp3+, CD25+TregsafterPC-61 treatment are shown in
Fig. 5. T cells are scattered through cortex and cluster in perivascular cuffs. (A–
C) Immunofluorescent labeling of MBP (red) and CD3ε (green) in coronal sec-
tions of C57BL/6 mouse brains from Flt3L-treated, Treg-depleted, 2-mo group.
All images are maximum projections of confocal stacks from the hemisphere
contralateral to the injection. A is from the dorsal cortex; B is from the lateral
striatum (str), external capsule (ec), and adjacent cortex (ctx); and C is from the
dorsal aspect of the corpus callosum (cc). (D) immunofluorescent labeling of
CD3ε (green) and laminin (red) in a coronal section of a C57BL/6 mouse from
Flt3L-treated, Treg-depleted, 2-wk group. Image is a single confocal section
taken from a ventromedial location within the injected striatum. Notice the
accumulation of T cells within perivascular cuffs. Yellow arrows indicate same
regions in different channels. (E) Immunoperoxidase labeling of CD3ε. (Left)
Image from a C57BL/6 mouse from Flt3L-treated, Treg-depleted, 2-wk group;
image is taken from dorsal striatum (str) of injected hemisphere. (Middle) Im-
age from same section, illustrating contralateral external capsule (ec) and ad-
jacent cortex (ctx). (Right) Image from a C57 mouse from the Flt3L-treated,
Treg-depleted, 2-mo group, captured in a location similar to that of theMiddle
image. (Scale bar, 100 μm.) Yellow arrows indicate perivascular cuffs.








SIAppendix, Fig. S2.At 7, 14, or 60dpostinjection, animalswereperfused for IHC,
or brains and spleens were collected for analysis of immune cell responses. IHC
and tissue processing are described in SI Appendix, SI Methods.
IFNγ ELISPOT and T-Cell Proliferation Assays. Splenocytes were assessed for
IFNγ secreting T lymphocyte frequency by ELISPOT, or T-cell proliferation by
BrdU incorporation with the following stimuli: His-HA protein (5 μg/mL), HA518
class I peptide (IYSTVASSL, 1 μg/mL), the HA class II peptide (HNTNGVTAACSHE,
1 μg/mL), MBP peptide (HTRTTHYGSLPQKSQHGR, 0.1 μg/mL), or PLP139 peptide
(HSLGKWLGHPDKF, 0.1 μg/mL).
Behavior and Statistical Analysis. Animals were tested in open-field, rotating
rod paradigms, and subjected to a battery of tests collectively known as
neuroscreen. Procedures are described in SI Appendix, SI Methods.
Quantitative data were subjected to one- or two-way ANOVA followed by
a Tukey–Kramer multiple comparison test using NCSS 2007 software. When
data failed normality or variance homogeneity tests, the data were square
root or log transformed before ANOVA.
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